AYA Sarcoma Survivors: Personalized Exercise Program Pilot

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-arm pilot evaluates feasibility of a modified EXCEEDS triage tool to refer AYAs with bone or soft tissue sarcoma to appropriate rehabilitation and exercise services at Dana-Farber. Part 2 offers a 12-week personalized exercise program, with some participants receiving gear like a Garmin monitor, resistance bands, and a stepper. The study measures changes in physical function and health-related quality of life before and after the program. About 40 participants will be involved in Part 1 and around 20 in the full study, with an expected total duration of about six months.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosed with a bone or soft tissue sarcoma
* Age 15-39 at time of diagnosis
* Age 15 and older at time of enrollment
* Age 15-17 at time of enrollment, with assent from participant and consent from parent/legal guardian
* Established patient of the DFCI Sarcoma Center or Jimmy Fund
* Able to read and understand English (to complete required questionnaires and participate in training/coaching)
* Individuals who are not yet adults (teenagers) if they assent and their parents/legal guardians' consent to participation.

Exclusion Criteria:

* Unstable cardiovascular disease in the last 6 months
* Psychiatric disorders or conditions that would preclude participation in the study intervention (e.g. untreated major depression or psychosis, untreated substance use disorder, severe personality disorder)
* Pregnant
* Currently participating in physical or occupational therapy
* Presence of medical conditions or medications that would prohibit participation in an exercise program
* Meeting exercise guidelines of 150 minutes of moderate intensity/75 minutes of vigorous intensity physical activity per week plus consistent strength training (at least once per week) over the past 3 months. Assessed via Godin Leisure Time Questionnaire by study staff.
* Adults unable to consent

Where it's running

• Boston Children's Hospital
  Boston, Massachusetts, United States Recruiting
• Brigham and Women's Hospital
  Boston, Massachusetts, United States Recruiting
• Dana-Farber Cancer Institute
  Boston, Massachusetts, United States Recruiting

Study contacts

• Principal investigator: Chao Cao, MD — Dana-Farber Cancer Institute
• Study coordinator: Chao Cao, MD
• Email: chao_cao@dfci.harvard.edu
• Phone: 617-632-4237

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Lifileucel (Tumor-infiltrating lymphocytes) for advanced soft tissue sarcoma

  This study tests lifileucel, a cell therapy made from a patient’s own tumor cells, in adults with unresectable or metastatic soft tissue sarcoma who have had prior treatments to see if it helps shrink tumors and improve outcomes.

  Recruiting at 2 sites Phase 2 Iovance Biotherapeutics, Inc. · Tampa, Florida and 1 other locations · NCT07741877

• Personalised neoadjuvant therapy planning for adults with high‑risk soft tissue sarcoma

  This project tests whether analyzing tumor tissue and clinical data can help guide neoadjuvant chemotherapy decisions for adults with high‑risk soft tissue sarcomas.

  Recruiting Royal Marsden NHS Foundation Trust · London · NCT07432932

• Assessing early psychiatric referral effects on mental health in sarcoma patients

  This study tests whether getting early mental health support helps sarcoma patients feel less anxious and depressed while recovering from surgery.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 7 other locations · NCT06129903

• Strasbourg pST soft tissue sarcoma care patterns and survival

  This study looks back at how closely soft tissue sarcoma care in Strasbourg followed international guidelines and whether that related to overall survival, comparing patient care from 2010-2016 to 2017-2024.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07864870

• MIGHTY: CAR T cells targeting B7-H3 for pediatric, teen, and young adult sarcoma

  This Phase 1 trial tests autologous hBRCA84D CAR T cells in kids, teens, and young adults (1–24) with relapsed or refractory RMS, ES, or DSRCT to see if the therapy is feasible and safe.

  Recruiting at 2 sites Phase 1 University College, London · London and 1 other locations · NCT07751380

• Domatinostat with Sirolimus for relapsed or refractory sarcoma and osteosarcoma

  This study tests whether the cancer drugs domatinostat and sirolimus together can help adolescents and adults whose sarcoma or osteosarcoma has come back or stopped responding to standard therapy.

  Recruiting at 2 sites Phase 1/2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida and 3 other locations · NCT07725380

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.